Abnormalities/NNS
of/IN
p16/NN
,/,
p15/NN
and/CC
CDK4/NN
genes/NNS
in/IN
recurrent/JJ
malignant/JJ
astrocytomas/NNS
./.

Abnormalities/NNS
in/IN
the/DT
p16/NN
,/,
p15/NN
and/CC
CDK4/NN
genes/NNS
that/WDT
regulate/VBP
transition/NN
through/IN
the/DT
G1/NN
phase/NN
of/IN
the/DT
cell/NN
cycle/NN
have/VBP
been/VBN
implicated/VBN
in/IN
the/DT
malignant/JJ
progression/NN
of/IN
astrocytomas/NNS
./.
=====
The/DT
results/NNS
of/IN
the/DT
present/JJ
study/NN
demonstrate/VBP
that/IN
dysfunction/NN
of/IN
these/DT
genes/NNS
also/RB
occurs/VBZ
during/IN
recurrence/NN
of/IN
glial/JJ
tumors/NNS
that/WDT
were/VBD
highly/RB
malignant/JJ
at/IN
first/JJ
presentation/NN
./.
=====
Analysis/NN
of/IN
10/CD
matched/VBN
pairs/NNS
of/IN
high/JJ
grade/NN
malignant/JJ
astrocytomas/NNS
and/CC
their/PRP$
subsequent/JJ
recurrences/NNS
identified/VBD
three/CD
distinct/JJ
groups/NNS
./.
=====
The/DT
primary/JJ
and/CC
recurrent/JJ
tumors/NNS
in/IN
Group/NN
A/NN
did/VBD
not/RB
show/VB
structural/JJ
alterations/NNS
in/IN
the/DT
p16/NN
,/,
p15/NN
or/CC
CDK4/NN
genes/NNS
,/,
whereas/IN
homozygous/JJ
codeletion/NN
of/IN
p16/NN
and/CC
p15/NN
was/VBD
observed/VBN
in/IN
both/CC
primary/JJ
and/CC
recurrent/JJ
tumors/NNS
in/IN
Group/NN
B/NN
./.
=====
The/DT
primary/JJ
tumors/NNS
in/IN
Group/NN
C/NN
had/VBD
a/DT
normal/JJ
profile/NN
of/IN
p16/NN
,/,
p15/NN
and/CC
CDK4/NN
at/IN
presentation/NN
./.
=====
Upon/IN
recurrence/NN
,/,
however/RB
,/,
the/DT
tumors/NNS
sustained/VBD
either/CC
deletion/NN
of/IN
p16/NN
alone/RB
or/CC
codeletion/NN
of/IN
both/CC
p16/NN
and/CC
p15/NN
or/CC
amplification/NN
of/IN
CDK4/NN
./.
=====
Analysis/NN
of/IN
the/DT
molecular/JJ
differences/NNS
between/IN
primary/JJ
anaplastic/JJ
astrocytomas/glioblastomas/NNS
and/CC
their/PRP$
subsequent/JJ
recurrences/NNS
,/,
which/WDT
are/VBP
clinically/RB
indistinguishable/JJ
,/,
may/MD
provide/VB
better/JJR
therapeutic/JJ
options/NNS
for/IN
treatment/NN
./.